Lymph node metastasis in Chinese patients with clinical T1 non-small cell lung cancer: A multicenter real-world observational study.

abstract：INTRODUCTION:VATS pulmonary segmentectomy is increasingly proposed as a parenchyma-sparing resection for tumors smaller than 2 cm in diameter. The aim of this study was to compare short-term oncological results and local control in solid non-small cell lung cancers (NSCLCs) <2 cm surgically treated by intentional VATS ...

journal_title：Thoracic cancer

authors： Darras M,Ojanguren A,Forster C,Zellweger M,Perentes JY,Krueger T,Gonzalez M

更新日期：2020-12-03 00:00:00

abstract：:After an initial benefit, non-small-cell lung cancer (NSCLC) patients receiving therapy with tyrosine kinase inhibitors develop drug resistance through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in epidermal growth factor receptor-mutated and anaplastic lymphom...

journal_title：Thoracic cancer

authors： Mengoli MC,Orsi G,Lococo F,Grizzi G,Barbieri F,Bertolini F,Rossi G,Novello S

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the feasibility of using a combination of apatinib in the treatment of non-small cell lung cancer. Apatinib is a tyrosine kinase inhibitor which selectivelyacts on vascular endothelial growth factor receptor 2 (VEGFR-2) and has shown good efficacy in a variety of mali...

journal_title：Thoracic cancer

authors： Liu M,Wang X,Li H,Xu L,Jing L,Jiang P,Liu B,Li Y

更新日期：2019-10-01 00:00:00

abstract：:A 69-year-old woman visited our hospital complaining of right chest pain. Chest computed tomography showed a 55 × 45 mm tumor in the right upper lobe. Bronchoscopy revealed displaced anomalous B 1 and B 2+3 arising from the right main bronchus, and the patient was diagnosed with lung adenocarcinoma by transbronchial l...

journal_title：Thoracic cancer

authors： Tajima K,Uchida N,Sasamoto H,Okada T,Kohri T,Mogi A,Kuwano H

更新日期：2016-09-01 00:00:00

abstract：:In the past decade, a dramatic shift has been witnessed in cancer therapy in China. Although traditional cytotoxic chemotherapy still remains the treatment of choice for many malignancies, targeted therapies are now a component of treatment for many types of cancer, including lung cancer. As molecular target agents ar...

journal_title：Thoracic cancer

authors： Wang Y,Sun Y

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:The efficacy of amrubicin for relapsed small-cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third-line amrubicin chemotherapy in patients with extensive disease (ED)-SCLC. METHODS:We retrospectively analyzed the clinical rec...

journal_title：Thoracic cancer

authors： Sonehara K,Tateishi K,Fukushima T,Komatsu M,Yamamoto H,Koizumi T,Hanaoka M

更新日期：2019-09-01 00:00:00

abstract：:Here, we report two cases of advanced non-small cell lung cancer (NSCLC) in patients with negative driver genes who received ICI treatment for less than two years but continued to benefit from their administration after drug withdrawal. The first patient was diagnosed with left lung adenocarcinoma, cT1cN3M1c, stage IV...

journal_title：Thoracic cancer

authors： Shan Q,Wang H,Han X,Guo J,Wang Z

更新日期：2020-10-01 00:00:00

abstract：:Several authors have previously reported that patients with pulmonary combined large cell neuroendocrine cancer ( LCNEC) have a poor prognosis and there is no consensus on the treatment strategy for combined LCNEC as well as LCNEC. Here, we report the case of a long-term survivor with pulmonary combined LCNEC. The pat...

journal_title：Thoracic cancer

authors： Oda R,Okuda K,Yamashita Y,Sakane T,Tatematsu T,Yokota K,Endo K,Nakanishi R

更新日期：2020-07-01 00:00:00

abstract：BACKGROUND:Breast cancer is the most common cancer among women. Population-based cancer registration data from the National Central Cancer Registry were used to analyze and evaluate the incidence and mortality rates in China in 2013, providing scientific information for cancer prevention and control. METHODS:Pooled da...

journal_title：Thoracic cancer

authors： Zuo TT,Zheng RS,Zeng HM,Zhang SW,Chen WQ

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Currently, there are no standard regimens for metastatic breast cancer patients (MBC) who have failed ≥ 3 chemotherapy treatments. The aim of this study was to assess whether weekly low-dose bevacizumab-based regimens were well tolerated and would improve efficacy in MBC patients who had failed numerous ther...

journal_title：Thoracic cancer

authors： Zhai X,Hong R,Fan Y,Yuan P,Wang J,Sang D,Chen J,Zhao C,Ou K,Ma F,Xu B

更新日期：2018-05-01 00:00:00

abstract：BACKGROUND:Connective tissue disease increases the risk of lung cancer, but whether rheumatoid arthritis (RA) has an effect on the overall survival (OS) rate in this population has not been well studied. METHODS:Patients diagnosed with lung cancer between January 2015 and December 2017 were enrolled in this retrospect...

journal_title：Thoracic cancer

authors： Zhang L,Zhao Q,Yuan F,Liu M

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:We explored correlations between the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification, epidermal growth factor receptor (EGFR) mutation status, and prognosis. METHODS:Data from 293 patients with lung adenocarcinoma were classifi...

journal_title：Thoracic cancer

authors： Guo Z,Yi F,Yin W,Zhang Y,Li Q,Gu Y,Xiao Y,Cao B,Ma L,Liang L

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Malignant pleural mesothelioma (MPM) is an aggressive cancer refractory to current therapies. Reduced expression of micro ribonucleic acid (miR)-591 in a range of cancer types has suggested it is a potent tumor suppressor, and overexpression has been shown to inhibit tumor cell growth. The role of miR-591 in...

journal_title：Thoracic cancer

authors： Cheng S,Xu Y,Shi Z,Lin Y,Hoang CD,Zhang X

更新日期：2016-04-26 00:00:00

abstract：BACKGROUND:S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and...

journal_title：Thoracic cancer

authors： Imai H,Minemura H,Kishikawa T,Yamada Y,Suzuki K,Umeda Y,Wasamoto S,Kasahara N,Ishihara S,Yamaguchi O,Naruse I,Uchino J,Mori K,Kanazawa K,Shibata Y,Kasai T,Kaburagi T,Kaira K,Minato K

更新日期：2020-10-01 00:00:00

abstract：BACKGROUND:Esophageal cancer has a high mortality rate, particularly in Asia, and there are obvious racial differences in regard to incidence. The purpose of our study was to assess the genetic susceptibility of functional single nucleotide polymorphisms in flap endonuclease-1 (FEN1) in esophageal squamous cell carcino...

journal_title：Thoracic cancer

authors： Sang Y,Bo L,Gu H,Yang W,Chen Y

更新日期：2017-05-01 00:00:00

abstract：BACKGROUND:Next-generation sequencing (NGS) has been implemented in clinical oncology to analyze multiple genes and to guide targeted therapy; however, little is known about the performance of the Oncomine Dx Target Test compared with conventional single gene tests for detecting EGFR mutations. The objective of this st...

journal_title：Thoracic cancer

authors： Sakaguchi T,Iketani A,Furuhashi K,Nakamura Y,Suzuki Y,Ito K,Fujiwara K,Nishii Y,Katsuta K,Taguchi O,Hataji O

更新日期：2020-12-12 00:00:00

abstract：BACKGROUND:Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) may be necessary for patients with incidental lung cancer during or after coronary intervention. Although EBUS-TBNA is quite safe, the safety in patients who recently received percutaneous coronary intervention (PCI) has not been de...

journal_title：Thoracic cancer

authors： Gil HI,Choe J,Jeong BH,Um SW,Jeon K,Hahn JY,Kim H,Kwon OJ,Chang YS,Lee K

更新日期：2018-11-01 00:00:00

abstract：BACKGROUND:The impact of adjuvant treatment for esophageal carcinoma with tumor-negative lymph nodes after upfront radical esophagectomy is still uncertain. This study investigated the effects of postoperative radiotherapy in pT1-3N0 esophageal carcinoma after radical resection. METHOD:We retrospectively identified pT...

journal_title：Thoracic cancer

authors： Gao HJ,Shang XB,Gong L,Zhang HD,Ren P,Shi GD,Wei YC,Yu ZT

更新日期：2020-02-01 00:00:00

abstract：BACKGROUND:Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life-threatening adverse event. The purpose of this study was to evaluate whether the development of immune-related adverse events (irAEs), especially ILD, was associated with treatment efficacy and to research th...

journal_title：Thoracic cancer

authors： Sugano T,Seike M,Saito Y,Kashiwada T,Terasaki Y,Takano N,Hisakane K,Takahashi S,Tanaka T,Takeuchi S,Miyanaga A,Minegishi Y,Noro R,Kubota K,Gemma A

更新日期：2020-04-01 00:00:00

abstract：BACKGROUND:Lung cancer represents the highest morbidity and mortality caused by neoplasms in the world; therefore researchers continue to search for new tools to diagnose and treat the disease. The aim of the study was to establish the role of single nucleotide polymorphisms (SNP) in the promoter region of the human le...

journal_title：Thoracic cancer

authors： Kowal A,Wiśniewski A,Kuśnierczyk P,Jankowska R

更新日期：2015-09-01 00:00:00

abstract：BACKGROUND:Accumulated evidence has revealed that the dysregulation of micro ribonucleic acids (miRNAs) may contribute to esophageal squamous cell carcinoma (ESCC). MiR-93, which is a member of the miRNA cluster miR-106b∼25, has been widely studied for its tumor promoting effect on different types of cancers. However, ...

journal_title：Thoracic cancer

authors： Li C,Ding C,Chen T,Chen J,Xu Z,Lei Z,Xu C,Zhao J

更新日期：2015-07-01 00:00:00

abstract：:Almost all epidermal growth factor receptor (EGFR)-mutant lung cancers develop resistance to EGFR-tyrosine kinase inhibitors. Several mechanisms for this acquired resistance have been identified, including development of an EGFR T790M mutation, MET amplification, hepatocyte growth factor overexpression, loss of phosph...

journal_title：Thoracic cancer

authors： Xu S,Liu X,Liu R,Shi T,Li X,Zhong D,Wang Y,Chen G,Chen J

更新日期：2017-11-01 00:00:00

abstract：:The ALK gene encodes a transmembrane tyrosine kinase receptor. ALK is physiologically expressed in the nervous system during embryogenesis, but its expression decreases postnatally. ALK first emerged in the field of oncology in 1994 when it was identified to fuse to NPM1 in anaplastic large-cell lymphoma. Since then, ...

journal_title：Thoracic cancer

authors： Du X,Shao Y,Qin HF,Tai YH,Gao HJ

更新日期：2018-04-01 00:00:00

abstract：BACKGROUND:Patients with malignant pleural effusion have a limited life expectancy. An increase in pleural and oncological treatment options and more accurate prognostic evaluation may help individualize treatment strategies. The aim of this study was to identify the prognostic indicators of overall survival (OS) after...

journal_title：Thoracic cancer

authors： Yoon DW,Cho JH,Choi YS,Kim J,Kim HK,Zo JI,Shim YM

更新日期：2016-07-01 00:00:00

abstract：:Immune checkpoint inhibitors that block the programmed death 1/programmed death ligand 1 pathways are widely used to treat advanced lung cancers. There are seldom cases of histologic transformation reported after treatment with immunotherapy. Here, we report the case of a 69-year-old man with stage IV lung squamous ce...

journal_title：Thoracic cancer

authors： Si X,You Y,Zhang X,Wang H,Wang M,Zhang L

更新日期：2020-03-01 00:00:00

abstract：BACKGROUND:Achaete-scute homolog 1 (ASCL1) is a basic helix-loop-helix transcription factor and is essential in the differentiation of neuroendocrine cells and neural tissues. ASCL1 is frequently overexpressed in small cell lung cancer (SCLC) and plays a crucial role in the pathogenesis of SCLC. METHODS:This study was...

journal_title：Thoracic cancer

authors： Kim JH,Lee SY,Choi JE,Do SK,Lee JH,Hong MJ,Kang HG,Lee WK,Shin KM,Jeong JY,Choi SH,Lee YH,Seo H,Yoo SS,Lee J,Cha SI,Kim CH,Park JY

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:The aim of this study was to evaluate the cytotoxic and antitumor activity of spider venom (SV). METHODS:Cell proliferation and cytotoxicity were determined by 3 H-methyl thymidine incorporation ([3 H]-TDR) assay. DNA fragmentation and cell cycle kinetics were analyzed by FACS. In vivo inhibition of tumor s...

journal_title：Thoracic cancer

authors： Gao L,Zhang J,Liu X,Zhao M,Li L,Liu X,Zhao B

更新日期：2013-08-01 00:00:00

abstract：BACKGROUND:Non-small cell lung cancer (NSCLC) is a major type of lung cancer with high morbidity and high mortality. miR-874 has been determined to play a role in tumor suppression in several cancers. The purpose of our study was to detect the biological mechanisms of miR-874 and AQP3 in NSCLC. METHODS:CCK-8 and Trans...

journal_title：Thoracic cancer

authors： Wang S,Wu Y,Yang S,Liu X,Lu Y,Liu F,Li G,Tian G

更新日期：2020-06-01 00:00:00

abstract：BACKGROUND:The aim of this study was to investigate the patterns and influencing factors of local-regional recurrence of lower thoracic esophageal squamous cell carcinoma (TESCC) after curative resection and to delineate the clinical target volume (CTV) of postoperative radiotherapy (PORT). METHODS:From January 2009 t...

journal_title：Thoracic cancer

authors： Liu J,Cai X,Liu Q,Li H,Cheng Y,Fu X

更新日期：2017-11-01 00:00:00

abstract：:Double aortic arch (DAA) is a rare congenital anomaly of the heart and aorta in which a vascular ring that surrounds the trachea and esophagus is formed. In most patients, respiratory distress and dysphagia develop in childhood, and asymptomatic adult patients are rarely known. Herein, we describe a patient with lung ...

journal_title：Thoracic cancer

authors： Kawamoto N,Okita R,Inokawa H,Hayashi M,Furukawa M,Okada M,Okabe K

更新日期：2020-08-01 00:00:00